Nektar Therapeutics NKTR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/24/24 EDT
1.35quote price arrow down-0.03 (-2.17%)
Volume
3,598
Close
1.38UNCH (UNCH)
Volume
952,817
52 week range
0.41 - 1.75
Loading...
  • Open1.37
  • Day High1.42
  • Day Low1.37
  • Prev Close1.38
  • 52 Week High1.75
  • 52 Week High Date04/11/24
  • 52 Week Low0.41
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap253.393M
  • Shares Out183.62M
  • 10 Day Average Volume4.20M
  • Dividend-
  • Dividend Yield-
  • Beta0.75
  • YTD % Change144.25

KEY STATS

  • Open1.37
  • Day High1.42
  • Day Low1.37
  • Prev Close1.38
  • 52 Week High1.75
  • 52 Week High Date04/11/24
  • 52 Week Low0.41
  • 52 Week Low Date11/13/23
  • Market Cap253.393M
  • Shares Out183.62M
  • 10 Day Average Volume4.20M
  • Dividend-
  • Dividend Yield-
  • Beta0.75
  • YTD % Change144.25

RATIOS/PROFITABILITY

  • EPS (TTM)-1.46
  • P/E (TTM)-0.95
  • Fwd P/E (NTM)-1.80
  • EBITDA (TTM)-126.11M
  • ROE (TTM)-110.95%
  • Revenue (TTM)90.122M
  • Gross Margin (TTM)62.53%
  • Net Margin (TTM)-306.31%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Nektar Therapeutics

 

Content From Our Affiliates

Profile

MORE
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline...
Robert Chess
Independent Chairman of the Board
Howard Robin
President, Chief Executive Officer, Director
Sandra Gardiner
Interim Chief Financial Officer
Address
455 Mission Bay Boulevard South
San Francisco, CA
94158
United States

Top Peers

SYMBOLLASTCHG%CHG
GTHX
G1 Therapeutics Inc
3.99UNCHUNCH
TSVT
2Seventy Bio Inc
4.27UNCHUNCH
ENTA
Enanta Pharmaceuticals Inc
12.92UNCHUNCH
PSTX
Poseida Therapeutics Inc
2.07UNCHUNCH
RIGL
Rigel Pharmaceuticals Inc
1.12UNCHUNCH